INTERVIEWS

Leading cardiologist, Dr. Ross Walker, discusses a new study published in “Heart, Lung and Circulation” (published by Elsevier for the Australian and New Zealand Society of Cardiac and Thoracic Surgeons and the Cardiac Society of Australia and New Zealand) that evaluates ubiquinol, the active form of the powerful antioxidant CoEnzyme Q10, for heart health in patients who are taking cholesterol management medication.

Jay Baker, President of Jamestown Plastics™, a custom manufacturer of thermoformed products, talks about how he and his team did a “pandemic pivot” and created and manufactured face shields to prevent the spread of coronavirus. Jay felt it was his responsibility to immediately help create a solution that would address the needs of First Responders to be safe within his local community. Thus, True Hero™ Extreme Coverage Shield was born.

Dr. Thorsten Leucker,  Assistant Professor of Medicine in the Division of Cardiology, Department of Medicine at the Johns Hopkins University School of Medicine discusses a study, EVACS (Evolocumab in Acute Coronary Syndrome) evaluating a hospital-based intervention option in ACS patients that was published in the American Heart Association’s journal, “Circulation”.  The study examined LDL-C reduction in non-ST-elevation myocardial infarction (NSTEMI) patients that met certain criteria. 

Returning guest, Dr. Kimberly Smith, Head of Research and Development at ViiV Healthcare discusses recent advancements made in HIV studies and the impact COVID-19 has had on R&D efforts.

Dr. Barbara White, Chief Medical Officer and Head of Research at Corbus Pharmaceuticals discusses Lenabasum, Corbus’ lead drug candidate that activates the often underutilized endocannabinoid system (ECS) to treat systemic sclerosis. Its Phase III trial recently completed treatment and is projected to release its data by the end of summer 2020.

Dr. Paul Wotton, CEO of Obsidian Therapeutics, discusses Obsidian’s platform, cytoDRiVE™, that regulates protein levels in cell and gene therapies, creating an “operating system” for living drugs. This means that now, and for the first time, physicians will be able to control genetically-engineered cells’ biologic activity to increase efficacy and reduce toxicity, using easily accessed generics and other FDA-approved drugs.

Returning guest, Daniel Simon, SVP, BioPharma Business Development at Guardant Health, a leading precision oncology company discusses a strategic collaboration with Radius Health for the commercialization and use of the Guardant360® CDx  liquid biopsy companion diagnostic for elacestrant (RAD1901), an investigational therapy being studied for the treatment of advanced breast cancer in combination with hormone therapy.

Dr. Dennis Hruby, Ph.D., Chief Scientific Officer at SIGA Technologies, Inc., discusses lessons we are currently learning from the COVID-19 pandemic and whether America will be truly prepared for the next pandemic based on this one.  He also talks about how healthcare will change in the future as a result of the current pandemic.

Dr. Phillip Gomez, Ph.D., CEO at SIGA Technologies, Inc., discusses how the field of Health Security has transformed after the anthrax attacks in the United States in late 2001.  He also talks about the potential for a smallpox bioterror attack and how would it compare with the current COVID-19 pandemic. 

Peter Rosenberger, the host of the national radio show “Hope For The Caregiver” and caregiver for over 34 years to his wife Gracie (a double amputee) who recently recovered from COVID-19, discusses his testing positive for COVID-19 three months after his wife’s recovery.